Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)

BackgroundBased on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins. In this study we have seen the association of HLA genes with different types of bcr-abl transcripts. The association could predict the bcr-abl peptide presentation by particular HLA molecules.MethodsThe study included a total of 189 patients of mixed ethnicity with chronic myelogenous leukemia and acute lymphocytic leukemia who were being considered for bone marrow transplantation. Typing of bcr-abl transcripts was done by reverse transcriptase PCR method. HLA typing was performed by molecular methods. The bcr-abl and HLA association was studied by calculating the relative risks and chi-square test.ResultsSignificant negative associations (p < 0.05) were observed with HLA-A*02 (b2a2, e1a2), -A*68 (b2a2, b3a2, e1a2), -B*14 (b2a2, b3a2, e1a2), -B*15 (b2a2, b3a2), -B*40 (b2a2), -DQB1*0303 (b2a2, b3a2), -DQB1*0603 (b2a2), -DRB1*0401 (e1a2), -DRB1*0701 (b3a2), and -DRB1*1101 (b2a2).ConclusionsThe negative associations of a particular bcr-abl transcript with specific HLA alleles suggests that these alleles play a critical role in presenting peptides derived from the chimeric proteins and eliciting a successful T-cell cytotoxic response. Knowledge of differential associations between HLA phenotypes and bcr-abl fusion transcript types would help in developing better strategies for immunization with the bcr-abl peptides against t(9;22) (q34;q11)-positive leukemia.

[1]  O. Tsitsilonis,et al.  Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor , 2000, The Journal of Immunology.

[2]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[3]  F. Lemonnier,et al.  Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. , 1998, The Journal of clinical investigation.

[4]  Y. Aizawa,et al.  Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients , 1999, Leukemia.

[5]  J. Spivak,et al.  Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497 , 2000 .

[6]  G. Pawelec,et al.  Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML? , 2001, Leukemia.

[7]  G. Daley,et al.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.

[8]  S. Weiss,et al.  MHC class II—Restricted presentation of intracellular antigen , 1991, Cell.

[9]  C. Melief,et al.  Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. , 1996, Blood.

[10]  S. Smith,et al.  A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia , 1987, Nature.

[11]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[12]  G. Saglio,et al.  New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. , 1990, Blood.

[13]  R. Klausner,et al.  Class II MHC molecules can use the endogenous pathway of antigen presentation , 1990, Nature.

[14]  R. Clark,et al.  b3a2 BCR–ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia , 2000, British journal of haematology.

[15]  C. Creaser,et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. , 2001, Blood.

[16]  Y. Nishimura,et al.  CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. , 1998, Blood.

[17]  O. Witte,et al.  Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells , 1989, Molecular and cellular biology.

[18]  J. McKenzie,et al.  HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. , 1997, Blood.

[19]  J. van Bergen,et al.  A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. , 1999, Blood.

[20]  J. Stephenson,et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.

[21]  J. Melo,et al.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.

[22]  G. Meloni,et al.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) , 1996, Blood.

[23]  Tokiharu Takahashi,et al.  Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide. , 2002, Leukemia research.

[24]  A. Chase,et al.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993, Blood.

[25]  R. Kurzrock,et al.  KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. , 1995, Leukemia.

[26]  H. Hirai,et al.  Generation of HLA‐DRB1*1501‐restricted p190 minor bcr–abl (e1a2)‐specific CD4+ T lymphocytes , 2000, British journal of haematology.

[27]  P. Cano,et al.  A geometric study of the amino acid sequence of class I HLA molecules , 1998, Immunogenetics.

[28]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[29]  D. Accapezzato,et al.  Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes , 1996 .

[30]  Eric O Long,et al.  Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells , 1992, Nature.

[31]  C. Melief,et al.  Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. , 1995, Leukemia.

[32]  N. Heisterkamp,et al.  The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript , 1986, Molecular and cellular biology.

[33]  Pedro Cano,et al.  A geometric and algebraic view of MHC-peptide complexes and their binding properties , 2001, BMC Structural Biology.

[34]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[35]  N. Heisterkamp,et al.  Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia , 1987, Cell.

[36]  J. Falkenburg,et al.  HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. , 1999, Blood.

[37]  D. Catovsky.  Ph1‐POSITIVE ACUTE LEUKAEMIA AND CHRONIC GRANULOCYTIC LEUKAEMIA: ONE OR TWO DISEASES? , 1979, British journal of haematology.

[38]  R. Lechler,et al.  Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. , 1994, Leukemia.

[39]  S. Soignet,et al.  Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. , 2000, Blood.

[40]  A. Sette,et al.  Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.

[41]  J. Falkenburg,et al.  HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML) , 2000, Leukemia.

[42]  B. Dörken,et al.  Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia , 2000, Bone Marrow Transplantation.

[43]  A. Hasegawa,et al.  HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. , 2001, Blood.

[44]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[45]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[46]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .

[47]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.